Combined Low-Dose Cetuximab and Green Tea Epigallocatechin-3-Gallate Treatment Induces Lung Cancer Cell Death

Basit Öğe Kaydı
dc.contributor.authorErdogan, Ayse
dc.date.accessioned2026-01-24T12:30:58Z
dc.date.available2026-01-24T12:30:58Z
dc.date.issued2025
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractGreen tea catechins, especially epigallocatechin-3-gallate (EGCG), have been associated with cancer prevention and treatment. Cetuximab is a chimeric monoclonal antibody that is directed toward the epidermal growth factor receptor (EGFR). The use of EGCG could enhance the effect of cetuximab through additive or synergistic effects as well as through amelioration of deleterious side effects. Cytotoxic, antiproliferative, cell-cycle-inhibitory, oxidative, and apoptotic effects of cetuximab alone and together with EGCG on A-549 and H1299 cells were investigated. EGCG enhanced cytotoxic effect of cetuximab on all cells. Lactate dehydrogenase activity, as a result of cell death, was found to be at the highest level at treatment of cetuximab with EGCG in all cells. Treatment of cetuximab with EGCG was found to be more effective at increasing glutathione peroxidase activity than cetuximab alone. Proliferating Cell Nuclear Antigen (PCNA), topoisomerase II-alpha, cyclin D1, cyclin D2, cyclin E, cyclin A, and cyclin B gene expression was decreased in all cells, which explains the cell-cycle-inhibitory effect. Both cetuximab alone and in combination treatments caused an increase in the Bax/Bcl-2 ratio in both type of cell. These findings suggest that treatment of cetuximab combined with EGCG might exhibit more carcinogenesis-reducing potential than cetuximab alone.
dc.description.sponsorshipAlanya Alaaddin Keykubat University Scientific Research Projects Unit [2019-02-07-MAP01]
dc.description.sponsorshipThe author would like to thank Alanya Alaaddin Keykubat University Scientific Research Projects Unit (2019-02-07-MAP01) for the financial support of this work.
dc.identifier.doi10.1007/s11094-025-03462-5
dc.identifier.endpage848
dc.identifier.issn0091-150X
dc.identifier.issn1573-9031
dc.identifier.issue8
dc.identifier.scopus2-s2.0-105024922815
dc.identifier.scopusqualityQ4
dc.identifier.startpage837
dc.identifier.urihttps://doi.org/10.1007/s11094-025-03462-5
dc.identifier.urihttps://hdl.handle.net/20.500.12868/5554
dc.identifier.volume59
dc.identifier.wosWOS:001637685600001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofPharmaceutical Chemistry Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260121
dc.subjectepigallocatechin-3-gallate
dc.subjectcetuximab
dc.subjectapoptosis
dc.subjectlung cancer
dc.subjectcombined treatment
dc.titleCombined Low-Dose Cetuximab and Green Tea Epigallocatechin-3-Gallate Treatment Induces Lung Cancer Cell Death
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu